Navigation Links
The Female Health Company to Report FY2012 Operating Results on Tuesday, December 4, 2012
Date:11/27/2012

CHICAGO, Nov. 27, 2012 /PRNewswire/ -- The Female Health Company (NASDAQ-CM: FHCO) today announced that it will host an investor conference call to discuss its operating results for the quarter and fiscal year ended September 30, 2012 on Tuesday, December 4, 2012 at 11:00 a.m. Eastern Time (EST).  The Company expects to report its operating results earlier the same day.

(Logo: http://photos.prnewswire.com/prnh/20120712/MM39764LOGO)

Shareholders and other interested parties may participate in the conference call by dialing 1-877-374-8416 (international participants dial 1-412-317-6716) and asking to be connected to "The Female Health Company Conference Call" a few minutes before 11:00 a.m. EST on December 4, 2012.  A replay of the call will be available one hour after the call through 9:00 a.m. EST on Tuesday, December 18, 2012 by dialing 877-344-7529 (international callers dial 412-317-0088) and entering the conference ID 10021755.   

About The Female Health Company

The Female Health Company, based in Chicago, Illinois, manufactures and markets the FC2 Female Condom® (FC2), which is available in the U.S. and approximately 138 other countries globally.  The Company owns certain worldwide rights to the FC2 Female Condom®, including patents that have been issued by the U.S., the European Union, Canada, Australia, South Africa, Japan, The People's Republic of China, Spain, Mexico, Greece, Turkey and the African Regional Intellectual Property Organization (ARIPO), which includes Botswana, The Gambia, Ghana, Kenya, Lesotho, Malawi, Mozambique, Namibia, Sierra Leona, Somalia, Sudan, Swaziland, Uganda, United Republic of Tanzania, Zambia and Zimbabwe.  FC2 patent applications are pending in various countries.  The FC2 Female Condom® is the only available FDA-approved product controlled
'/>"/>

SOURCE The Female Health Company
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2

Related medicine technology :

1. Palatin Technologies Announces Last Patient Completed Treatment In Phase 2B Bremelanotide Female Sexual Dysfunction Trial
2. Attorneys for Class of Female VPs and SVPs Employed by PR Giant MSLGroup Clarify Companys Inaccurate Description of Federal Courts Recent Certification Ruling
3. The Female Health Company Reports Second Quarter Operating Results
4. Nouveau Life Pharmaceuticals (HRID) Contracts with U.S. Manufacturer to Produce New Female Supplement
5. Frost & Sullivan: U.S. Health Information Exchange Market Enters Prime Time in Rapidly Transforming Healthcare Industry
6. Collegium Pharmaceutical to Present at Piper Jaffrays 24th Annual Healthcare Conference
7. Boston Healthcare Expands Health Economics, Pricing, and Reimbursement Consulting Practice in Asia
8. Global Healthcare Analytics/Medical Analytics Market worth $10.8 Billion by 2017
9. Boston Healthcare estende i suoi servizi di consulenza su politica sanitaria, prezzi, e procedura di rimborso allarea asiatica
10. Boston Healthcare erweitert Gesundheitsökonomie-, Preis- und Vergütungsberatung in Asien
11. MetroStar Home Health Products Holds Sandy Relief Holiday Toy Drive
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/23/2014)... 2014  As physicians seek information about drugs ... to learn about new therapies or ask questions ... new report by global sales and marketing consultants ... via a customized mix of digital media and ... to engage with physicians. And, productive engagement with ...
(Date:9/22/2014)... BARCELONA , España, September 23, 2014 ... nube permite que los patrocinadores de ensayos clínicos satisfagan ... a la accesibilidad y exhaustividad de los expedientes permanentes ... La mayor encuesta sobre TMF en el ... un aumento en el número de patrocinadores de ensayos ...
(Date:9/22/2014)... Calif. , Sept. 22, 2014 Avanir ... that it is offering to sell $200 million of ... Morgan, Deutsche Bank Securities and BofA Merrill Lynch are ... to grant the underwriters a 30-day option to purchase ... shares to be sold in the offering are being ...
Breaking Medicine Technology:As sales reps see doors close for in-person visits with physicians, digital doors open communication 2As sales reps see doors close for in-person visits with physicians, digital doors open communication 3As sales reps see doors close for in-person visits with physicians, digital doors open communication 4As sales reps see doors close for in-person visits with physicians, digital doors open communication 5El acceso remoto al eTMF se duplicará en 2015, revela una encuesta general del sector 2El acceso remoto al eTMF se duplicará en 2015, revela una encuesta general del sector 3El acceso remoto al eTMF se duplicará en 2015, revela una encuesta general del sector 4El acceso remoto al eTMF se duplicará en 2015, revela una encuesta general del sector 5Avanir Pharmaceuticals Announces Proposed Public Offering of Common Stock 2Avanir Pharmaceuticals Announces Proposed Public Offering of Common Stock 3
... N.J., Oct. 31, 2011 Johnson & Johnson Pharmaceutical ... has submitted a supplemental New Drug Application (sNDA) to ... ® ER (tapentadol) extended-release tablets, an oral analgesic, ... peripheral neuropathy (DPN) in adults. The FDA approved NUCYNTA ...
... NEW YORK, Oct. 31, 2011 Reportlinker.com ... is available in its catalogue: ... 2016 http://www.reportlinker.com/p0254518/Germany-Surgical-Equipment-Market-Outlook-to-2016.html#utm_source=prnewswire&utm_medium=pr&utm_campaign=Surgical_Equipment ... to 2016 Summary ...
Cached Medicine Technology:Supplemental New Drug Application Submitted to FDA for NUCYNTA® ER (Tapentadol) Extended-Release Tablets for Diabetic Peripheral Neuropathic Pain 2Supplemental New Drug Application Submitted to FDA for NUCYNTA® ER (Tapentadol) Extended-Release Tablets for Diabetic Peripheral Neuropathic Pain 3Supplemental New Drug Application Submitted to FDA for NUCYNTA® ER (Tapentadol) Extended-Release Tablets for Diabetic Peripheral Neuropathic Pain 4Supplemental New Drug Application Submitted to FDA for NUCYNTA® ER (Tapentadol) Extended-Release Tablets for Diabetic Peripheral Neuropathic Pain 5Supplemental New Drug Application Submitted to FDA for NUCYNTA® ER (Tapentadol) Extended-Release Tablets for Diabetic Peripheral Neuropathic Pain 6Supplemental New Drug Application Submitted to FDA for NUCYNTA® ER (Tapentadol) Extended-Release Tablets for Diabetic Peripheral Neuropathic Pain 7Supplemental New Drug Application Submitted to FDA for NUCYNTA® ER (Tapentadol) Extended-Release Tablets for Diabetic Peripheral Neuropathic Pain 8Supplemental New Drug Application Submitted to FDA for NUCYNTA® ER (Tapentadol) Extended-Release Tablets for Diabetic Peripheral Neuropathic Pain 9Supplemental New Drug Application Submitted to FDA for NUCYNTA® ER (Tapentadol) Extended-Release Tablets for Diabetic Peripheral Neuropathic Pain 10Supplemental New Drug Application Submitted to FDA for NUCYNTA® ER (Tapentadol) Extended-Release Tablets for Diabetic Peripheral Neuropathic Pain 11Supplemental New Drug Application Submitted to FDA for NUCYNTA® ER (Tapentadol) Extended-Release Tablets for Diabetic Peripheral Neuropathic Pain 12Supplemental New Drug Application Submitted to FDA for NUCYNTA® ER (Tapentadol) Extended-Release Tablets for Diabetic Peripheral Neuropathic Pain 13Germany Surgical Equipment Market Outlook to 2016 2Germany Surgical Equipment Market Outlook to 2016 3Germany Surgical Equipment Market Outlook to 2016 4Germany Surgical Equipment Market Outlook to 2016 5Germany Surgical Equipment Market Outlook to 2016 6Germany Surgical Equipment Market Outlook to 2016 7Germany Surgical Equipment Market Outlook to 2016 8Germany Surgical Equipment Market Outlook to 2016 9
(Date:9/23/2014)... 23, 2014 On September 23, 2014, My ... for an episode. Simmons is the founder of Traveler of ... audience would like to know. At the start of the ... to start this magazine?” Simmons replied by saying, “I had ... In 2005, I quit that and decided to start my ...
(Date:9/23/2014)... The U.S. Pharmacopeial Convention (USP) has submitted ... (WHO) regarding the assignment of Biological Qualifiers (BQ) to ... Expert Group of the Programme of International Nonproprietary Names ... naming of all biologicals that is consistent with existing, ... these drugs. , Hence, USP supports the concept ...
(Date:9/23/2014)... Healthcare Solutions, the parent ... and Modern Medical, today announced the expansion ... with EMPLOYERS®, America's small business insurance specialist®. ... has saved millions of dollars in workers’ ... Since May 2013, Healthcare Solutions has worked ...
(Date:9/23/2014)... 2014 (HealthDay News) -- Fear of losing your job can ... European study. The study involved more than 7,000 employed ... downturn in Europe, the workers answered questions about the respiratory ... their job within two years. More than 100 new ... of whom were women, during the study period. The ...
(Date:9/23/2014)... (PRWEB) September 23, 2014 Altec ... and workflow solutions, will be a participating sponsor ... annual Microsoft Dynamics® GP customer conference, from 8:00am ... Meydenbauer Center in Bellevue, Washington. The Resource Group ... overcome challenges during growth and connect disparate ...
Breaking Medicine News(10 mins):Health News:My Positive Perspective Airs Episode With the Founder of Traveler of Charleston Magazine 2Health News:USP Comments to WHO Regarding Biologics Qualifier Proposal 2Health News:EMPLOYERS® Expands Pharmacy Services with Healthcare Solutions After Effective Pilot Program 2Health News:EMPLOYERS® Expands Pharmacy Services with Healthcare Solutions After Effective Pilot Program 3Health News:Job Worries Can Raise Asthma Risk, Study Says 2Health News:Altec to Sponsor The Resource Group’s Annual RG Connect Conference 2Health News:Altec to Sponsor The Resource Group’s Annual RG Connect Conference 3
... can be severe , , MONDAY, May 18 (HealthDay News) -- ... as it tries to serve the poor, researchers from North ... recovering from breast cancer do not take the drugs ... do not follow instructions to take these drugs, medications that ...
... CLC 27th Annual Conference on Professional Issues May 24 in ... Council, the leading nonprofit professional association serving child life specialists, ... recipient of the 2009 Distinguished Service Award, in recognition of ... Utica College was selected by ...
... retail locationNORTH BERGEN, N.J., May 18 Eco Shoppe has announced ... Eco Shoppe store in the country. Eco Shoppe is a ... products directly to consumers through exciting new stores as well as ... will open in Austin on May 21 and is owned and ...
... made on May 13, 2009, as Minnesota became the ... health provider into state statute - enabling students who ... model to become licensed to practice. The Minnesota ... a bill establishing the Dental Therapist and Advanced Dental ...
... Study Confirms Previous Positive Findings on Efficacy and ... Deutsche Bank 34th Annual Healthcare Conference Today at ... Neurocrine Biosciences, Inc. (Nasdaq: NBIX ) ... from its Phase IIb clinical trial known as ...
... study finds , , MONDAY, May 18 (HealthDay News) -- People ... chance of living a longer and healthier life. , Researchers ... data from 2002 to 2007, found that that wealthier people ... were less likely to have depression, high-blood pressure or diabetes ...
Cached Medicine News:Health News:Poor Women Seem to Be Skipping Breast Cancer Drugs 2Health News:Utica College to Receive Child Life Council Spirit of Giving Award 2Health News:Utica College to Receive Child Life Council Spirit of Giving Award 3Health News:First Eco Shoppe Opening in Austin on May 21 2Health News:First Eco Shoppe Opening in Austin on May 21 3Health News:First Eco Shoppe Opening in Austin on May 21 4Health News:Minnesota Passes Legislation Allowing Mid-level Oral Health Provider 2Health News:Minnesota Passes Legislation Allowing Mid-level Oral Health Provider 3Health News:Neurocrine Announces Full Year Results from 603 Study (Petal Study) of Elagolix for Treatment of Endometriosis Pain 2Health News:Neurocrine Announces Full Year Results from 603 Study (Petal Study) of Elagolix for Treatment of Endometriosis Pain 3Health News:Neurocrine Announces Full Year Results from 603 Study (Petal Study) of Elagolix for Treatment of Endometriosis Pain 4Health News:Neurocrine Announces Full Year Results from 603 Study (Petal Study) of Elagolix for Treatment of Endometriosis Pain 5Health News:Money May Matter, Health-Wise, in Old Age 2
... GE Healthcare is ... in best-in-class analysis programs ... area monitoring device. With ... 12SL, Gender-Specific, and ACI-TIPI, ...
... The Affinity pacemaker family ... smallest, truly automatic devices. ... combination of advanced technologies ... DR pacemaker incorporates the ...
... small bench top chemistry analyzer that utilizes dry ... with results available within 8 - 15 minutes. ... instrument accepts whole blood samples and is calibrated ... At the conclusion of testing, results are available ...
... is a battery-backed up, microprocessor based, quality instrument ... It stores and displays a chart on its ... scrolled through or zoomed into and out of, ... to 3 months can be seen at one ...
Medicine Products: